CTOs on the Move

Outpost Medicine

www.outpostmedicine.com

 
At Outpost, we are committed to developing novel therapeutics for the treatment of gastrointestinal and urologic disorders. The company`s lead clinical-stage product candidate is in development for the treatment of overactive bladder (OAB) and irritable bowel syndrome (IBS). ​Located in Indianapolis and London, Outpost is a private company launched in 2016 with a $61 million Series A venture capital financing from Frazier Healthcare Partners, Adams Street Partners, Novo Holdings A/S, Vivo Capital, and Takeda Ventures.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Outpost Medicine raised $20M on 11/15/2017

Similar Companies

Nurix Therapeutics

Nurix Therapeutics discovers drugs that harness the body`s natural process to control protein levels. Our drugs control ubiquitin E3 ligases, the key enzymes responsible for protein breakdown in human cells, as a unique therapeutic approach to treat a broad range of diseases. Our focus is on developing drugs to treat cancer including novel, small molecule immuno-oncology agents.

Cajal Neuroscience

Cajal Neuroscience is a drug discovery company focused on neurodegenerative disease.

Slingshot Biosciences

Making advanced diagnostics and adoptive cell therapies more accessible by working from the bottom up via synthetic cells.

InterVenn Biosciences

Clinical Glycoproteomics + Artificial Intelligence

Bolt Biotherapeutics

Bolt Biotherapeutics is a start-up with compelling technology from Dr. Engleman`s Lab at Stanford University, which demonstrated complete cures in numerous cancer models.